RxDoctor Payments Data

Kimberly Kreikemeier, PA

Medical · Omaha, NENPI 1710125240

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,074 of the $1,719 with a category attached, or 62.5%. Intuitive Surgical accounts for 82.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $1,399 and has fallen 98.9% since, to $15 in 2025.

$1,719in general payments, 2019–2025

Across 27 payments — averaging $63.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Boehringer Ingelheim$86
  • Grifols USA, LLC$52
  • Jazz Pharmaceuticals Inc.$42
  • Harmony Biosciences LLC$36
  • Amgen$19
  • plus $71 from 5 others

What the payments were for

  • Travel & lodging$63037%
  • Food & beverage$1,07462%
  • Gifts$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,719 in reported general payments places this provider in the 75th percentile of 216 medical providers in Nebraska.

See all medical providers in Nebraska

Medicare billing

Part B allowed, 2024
$9,563
Medicare patients
127
Services billed
190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$54,001
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$11,775
Spiriva HandihalerTiotropium Bromide11$5,356
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$2,362
Albuterol Sulfate HfaAlbuterol Sulfate29$558
Fluticasone Propionate13$228
Gabapentin21$195
Montelukast Sodium21$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$12$65,77693 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 216 medical providers in Nebraska.

Other medical in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →